-
Mashup Score: 48
Background An accurate method of assessing the response of muscle-invasive bladder cancer (MIBC) to neoadjuvant treatment is needed for selecting candidates for bladder-sparing strategies. Purpose To evaluate the diagnostic accuracy and reproducibility of neoadjuvant chemotherapy Vesical Imaging Reporting and Data System (nacVI-RADS) scores and posttreatment Vesical Imaging Reporting and Data System (VI-RADS) scores when assessing MIBC response to neoadjuvant immunotherapy with multiparametric MRI (mpMRI). Materials and Methods A retrospective analysis of MRI scans was conducted in patients enrolled in the PURE-01 study (NCT02736266) from February 2017 to December 2019 who underwent pre- and postimmunotherapy mpMRI before radical cystectomy. Five readers independently reviewed the scans using VI-RADS and nacVI-RADS criteria. Diagnostic accuracy was evaluated for each reader, and the final histopathologic diagnosis served as the reference standard. Interreader agreement was assessed wit
Source: pubs.rsna.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1) - 3 month(s) ago
PURPOSECisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard of care for patients with muscle-invasive bladder cancer (MIBC). Mutations in DNA damage repair genes are associated with pathologic downstaging after NAC. We …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Timely after our Milan consensus meeting on clinical CR - RETAIN 1 is out @JCO_ASCO @ERPlimackMD @ASCO https://t.co/7NaRh5vwYi
-
-
Mashup Score: 41Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours - 3 month(s) ago
Nature – A study reporting the results of a clinical trial co-administering the GDF-15-blocking antibody visugromab with the anti-PD-1 antibody nivolumab demonstrates that neutralizing GDF-15 can…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Fascinating story behind this! Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours @Nature The neoadjuvant #NeoGDFather trial in MIBC with nivo +/- visugromab is close to end accrual @DrIacovelli https://t.co/XetDkmQTDH
-
-
Mashup Score: 29Promises and Challenges of Dietary Intervention in Patients With Prostate Cancer: Lessons Learned From the CAPFISH-3 Trial - 3 month(s) ago
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center. Open Payments is a public database containing
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
@NazliDizman hits simultaneously to #GURetreat24 @JCO_ASCO @ASCO @urotoday @Medscape @OncoAlert Promises and Challenges of Dietary Intervention in Patients With Prostate Cancer: Lessons Learned From the CAPFISH-3 Trial | Journal of Clinical Oncology https://t.co/DEJVqqDKTk
-
-
Mashup Score: 2ClinicalTrials.gov - 3 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet-
https://t.co/K3vcZ8wUyi
-
-
Mashup Score: 41Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours - 3 month(s) ago
Nature – A study reporting the results of a clinical trial co-administering the GDF-15-blocking antibody visugromab with the anti-PD-1 antibody nivolumab demonstrates that neutralizing GDF-15 can…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Fascinating story behind this! Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours @Nature The neoadjuvant #NeoGDFather trial in MIBC with nivo +/- visugromab is close to end accrual @DrIacovelli https://t.co/XetDkmQTDH
-
-
Mashup Score: 66
Considerations for a multidisciplinary discussion about treatment for patients with lymph node involvement from MIBC are multifold, including radical cystectomy versus bladder preservation, novel neoadjuvant therapies, and side effect management. However, recent and ongoing clinical trials have provided potential new options for this patient population.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Bladder Preservation vs Radical Cystectomy in Locally Advanced Muscle-Invasive Bladder Cancer: Selecting Treatment for Patients in an Evolving Therapy Landscape @ASCO https://t.co/vRLCrbfbev
-
-
Mashup Score: 41Expopoint - 4 month(s) ago
MILANO – IRCCS Ospedale San Raffaele, Venerdì 13 Dicembre 2024 Nell’ ultimo decennio, l’ oncologia urologica ha conosciuto uno sviluppo significativo dell’ attivit à multidisciplinare, con urologi, oncologi, radioterapisti e medici nucleari coinvolti nel trattamento sempre pi ù complesso dei tumori urogenitali. Le innovazioni nelle tecniche chirurgiche e radioterapiche e l’ aumento del numero di farmaci oggi disponibili rendono necessario un aggiornamento continuo dei percorsi diagnostici e terapeutici
Source: www.expopoint.itCategories: General Medicine News, Hem/OncsTweet-
One month left #GURetreat24 https://t.co/7wLIEJ83kF @SanRaffaeleMI @MyUniSR @GTumors @IBCG_BladderCA @UroDocAsh @PGrivasMDPhD @SpiessPhilippe @shilpaonc @y_loriot @montypal @neerajaiims @NazliDizman @Albert0Briganti @_alelarcher @BrigidaMaiorano @CMercinelli @vale_tateo… https://t.co/2RnRxE20N7 https://t.co/YtEK0iO1hr
-
-
Mashup Score: 39Expopoint - 4 month(s) ago
MILANO – IRCCS Ospedale San Raffaele, Venerdì 13 Dicembre 2024 Nell’ ultimo decennio, l’ oncologia urologica ha conosciuto uno sviluppo significativo dell’ attivit à multidisciplinare, con urologi, oncologi, radioterapisti e medici nucleari coinvolti nel trattamento sempre pi ù complesso dei tumori urogenitali. Le innovazioni nelle tecniche chirurgiche e radioterapiche e l’ aumento del numero di farmaci oggi disponibili rendono necessario un aggiornamento continuo dei percorsi diagnostici e terapeutici
Source: www.expopoint.itCategories: General Medicine News, Hem/OncsTweet-
One month left #GURetreat24 https://t.co/7wLIEJ83kF @SanRaffaeleMI @MyUniSR @GTumors @IBCG_BladderCA @UroDocAsh @PGrivasMDPhD @SpiessPhilippe @shilpaonc @y_loriot @montypal @neerajaiims @NazliDizman @Albert0Briganti @_alelarcher @BrigidaMaiorano @CMercinelli @vale_tateo… https://t.co/2RnRxE20N7 https://t.co/YtEK0iO1hr
-
-
Mashup Score: 36
A continuous increase in testicular germ cell tumor (TGCT) cases is expected in the future. Genetic predisposition accounts for less than half of the TGCT heritability, and unrecognized prenatal and postnatal factors may also influence the risk of developing TGCT.
Source: www.europeanurology.comCategories: General Medicine News, Hem/OncsTweet-
All you need to know about Epidemiology and Risk Factors for Testicular Cancer by @vale_tateo @SpiessPhilippe et al. @GTumors @EUplatinum @SanRaffaeleMI @MyUniSR https://t.co/5FdQpO3HVD
-
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI | Radiology https://t.co/TJDjFtr2EC